Edition:
United Kingdom

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.43USD
14 Dec 2017
Change (% chg)

$-0.04 (-2.72%)
Prev Close
$1.47
Open
$1.46
Day's High
$1.50
Day's Low
$1.43
Volume
7,156
Avg. Vol
29,153
52-wk High
$4.83
52-wk Low
$1.29

Chart for

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $67.53
Shares Outstanding(Mil.): 33.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

* CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA

12 Dec 2017

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

14 Nov 2017

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

12 Sep 2017

BRIEF-Basilea says distribution agreement with Cardiome

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL

12 Sep 2017

BRIEF-Cardiome provides U.S. regulatory update for BRINAVESS

* Cardiome Pharma Corp - ‍FDA advised Cardiome that data package proposed by Cardiome would not be sufficient to support a resubmission of BRINAVESS NDA​

21 Aug 2017

BRIEF-Cardiome Pharma reports quarterly loss per share $0.26

* Q2 earnings per share view $-0.17, revenue view $7.1 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Cardiome Pharma Q2 loss per share $0.26

* Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Cardiome Pharma announces Health Canada approval of AGGRASTAT high dose bolus regimen

* Cardiome announces Health Canada approval of Aggrastat high dose bolus regimen

17 Jul 2017

BRIEF-Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT

* Cardiome's partner steadymed submits u.s. New drug application for trevyent® for the treatment of pulmonary arterial hypertension

03 Jul 2017

Competitors

Earnings vs. Estimates